Margaret McCartney: Flibanserin for low sexual desire is not feminism

M. McCartney
DOI: https://doi.org/10.1136/bmj.h5650
2015-10-26
British Medical Journal
Abstract:The UK Medicines and Healthcare Products Regulatory Agency will neither confirm nor deny it, but flibanserin is likely to be coming to British shores. Its maker, Sprout Pharmaceuticals, told me that it is “committed to working closely with other regulatory bodies outside the US . . . to bring to market a safe and effective treatment for the millions of women around the world affected by distressing low sexual desire.” The drug was licensed at the third attempt in the United States for the treatment of hypoactive sexual desire in premenopausal women.1 Ironically, a pressure group used the feminism argument to push for the US Food and Drug Administration’s approval on grounds of equality (men have their drugs; we want ours), when …
What problem does this paper attempt to address?